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T
here has been a recent and 
dramatic rise in global funding 
for HIV/AIDS, from US$2.1 
billion in 2001 to US$6.1 billion in 
2004 [1], thanks to several new funding 
mechanisms (Box 1). These funds, 
coupled with reduced drug costs, make 
it feasible to roll out antiretroviral 
therapy (ART) even in resource-poor 
settings. Nevertheless, the total number 
of people living with HIV rose in 
2004 to reach its highest level ever: an 
estimated 39.4 million people are living 
with the virus, including 4.9 million 
who acquired it in 2004 [1]. Therefore, 
the debate over the appropriate 
distribution of money between 
prevention efforts (such as voluntary 
counseling and testing [VCT], or 
behavior change) and treatment efforts 
(the provision of ART) is now more 
topical than ever. 
Balancing Prevention 
and Treatment
The scale of the proposed increase in 
the number of patients receiving ART 
raises numerous questions about the 
treatment itself. Which drugs will be 
used? How much will it cost? How will 
their quality be monitored and assured? 
How will they be distributed? Who will 
be eligible? How will the desired level 
of treatment be sustained? Is there 
adequate infrastructure and human 
resources to support the expanded 
services? 
The commitment of substantial 
funding to treatment in resource-poor 
countries also has implications for 
the prevention efforts in those same 
countries. In many Western countries 
and Brazil (the sources of the majority 
of the available data on the subject), 
the impressive drop in mortality due to 
HIV following increased access to ART 
is coupled with a disheartening rise 
in the number of new cases of HIV, as 
emphasis and funding are shifted from 
prevention to treatment [2]. Countries 
in which this pattern has been seen 
are evidence of the pitfalls of failing 
to adapt prevention efforts once life-
extending treatment becomes widely 
available. 
Of course, prevention and treatment 
are not mutually exclusive. Successful 
prevention efforts mean fewer 
patients will need the costly drug 
treatment programs, helping extend 
the sustainability of ART. In turn, 
the success of ART in prolonging 
healthy living helps prevention efforts 
by reducing the stigma associated 




In their study in the January 2005 
issue of PLoS Medicine, “Integrating 
HIV Prevention and Treatment: From 
Slogans to Impact,” Salomon and 
colleagues use mathematical modeling 
to assess the epidemiologic impact 
of treatment and prevention efforts, 
and to quantify the opportunities and 
potential risks of large-scale treatment 
roll-out. Using a variety of different 
scenarios, they propose methods for 
establishing the most effective balance 
between spending on prevention and 
spending on treatment. 
Modeling is a technique used 
by many scientists, including 
epidemiologists and statisticians, 
to create a mathematical equation 
that can be used to determine 
which variables affect an outcome of 
interest, and to what extent. Once the 
inﬂ  uential variables are determined, 
a baseline model is established that 
includes those variables and reﬂ  ects 
their relative importance to the 
outcome. The effect of changing the 
value of any of these variables, or 
several of them, can then be tested, 
and new outcomes projected. HIV 
modeling is inexact and requires 
far better data but can nevertheless 
provide important insights.
Salomon and colleagues used 
mathematical modeling to assess 
the effect of changing aspects of 
the HIV/AIDS “equation” on the 
future course of the HIV/AIDS 
epidemic. First, a baseline model was 
created to ﬁ  t expected HIV/AIDS 
projections for the year 2020 if there 
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Box 1. Initiatives to Fund ART
• The WHO “3 by 5” Initiative: This 
initiative aims to place 3 million people 
in low- and middle-income countries on 
ART by the end of 2005. 
• The US President’s Emergency Plan 
for HIV/AIDS Relief: This initiative aims 
to treat 2 million HIV-infected people 
with ART, to prevent 7 million new 
infections, and to care for 10 million HIV-
infected individuals and AIDS orphans in 
ﬁ  ve years (2004–2009).
• The Global Fund to Fight AIDS, 
Tuberculosis, and Malaria: In the ﬁ  ve 
years following its inception (2002–2007), 
the Global Fund aims to provide 1.6 
million people with ART and 52 million 
people with VCT, and to support more 
than 1 million orphans with medical 
services, education, and community care. PLoS Medicine  |  www.plosmedicine.org 0103
were to be no change in the current 
epidemiologic trends—no ART scale-
up, and no changes in prevention 
efforts or behavior. Heterosexual 
contact is the predominant mode 
of HIV transmission across Africa, 
and Salomon and colleagues’ study 
modeled the disease only within the 
heterosexual population. The model 
was also tailored to take into account 
epidemiologic, demographic, and 
sociologic patterns in the eastern, 
central/western and southern regions 
of Africa. Using the baseline models 
tailored to each region, the effects of 
prevention and treatment efforts were 
then measured. 
Two treatment-centered scenarios 
were tested in which the World Health 
Organization’s “3 by 5” initiative (see 
Box 1) was achieved. In these treatment-
centered scenarios, the reduction of 
transmissibility, the number of partners 
of each patient, and condom use were 
either optimal (reduced transmissibility, 
reduced partners, and increased 
condom use) or less than optimal. The 
prevention-centered scenario tested 
the impact of a comprehensive package 
of 12 prevention tools (such as VCT 
and peer counseling for sex workers), 
modeling only partial effectiveness at 
the population level, to reﬂ  ect weaker 
political and social support for HIV 
control efforts. Finally, combined 
response scenarios were tested. In 
the ﬁ  rst scenario, treatment efforts 
strengthened prevention efforts as, 
for example, when the availability of 
ART increases people’s willingness 
to undergo testing. In the second, 
an emphasis on treatment led to less 
effective implementation of prevention 
efforts. 
Baseline projections in Salomon and 
colleagues’ study showed that without 
any behavioral change or ART scale-up, 
the HIV/AIDS prevalence rate would 
remain relatively stable, but the number 
of new infections would increase by 52.3 
million by 2020. Treatment-centered 
scenarios reduced the total number 
of new infections through 2020 by a 
maximum of 3 million, or 6%, while 
indicating that the number of AIDS 
deaths through 2020 would decline 
by 13%, to 32.4 million. A prevention-
centered strategy would provide greater 
reductions in incidence (36%) and 
similar mortality reductions by 2020, 
but more modest mortality beneﬁ  ts over 
the next ﬁ  ve to ten years. 
The scenarios in which all of 
these statistics were most improved, 
however, were those that combined 
both prevention and treatment efforts. 
In the scenario in which treatment 
enhanced prevention, Salomon and 
colleagues projected 29 million averted 
infections (55%) and 10 million 
averted deaths (27%) through the year 
2020. However, if a narrow focus on 
treatment scale-up leads to reduced 
effectiveness of prevention efforts, the 
beneﬁ  ts of a combined response would 
be considerably smaller—9 million 
averted infections (17%) and 6 million 
averted deaths (16%) (Figure 1).
Combining treatment with effective 
prevention efforts could reduce 
the resource needs for treatment 
dramatically in the long term. In the 
various scenarios the numbers of people 
being treated in 2020 ranges from 9.2 
million in a treatment-only scenario 
with mixed effects, to 4.2 million in 
a combined response with positive 
treatment–prevention synergies. 
Moving Forward
The authors have demonstrated 
through mathematical modeling 
that the integration of treatment 
and prevention is epidemiologically 
sound. However, an integrated and 
comprehensive program (Figure 2) is 
not only logical but makes sense from 
the service delivery point of view: it 
can be cost-effective and ideal for the 
community. 
Effective prevention makes 
treatment more affordable and 
sustainable. Effective prevention can 
lead to a substantial reduction in 
the number of new infections and 
therefore ultimately will lead to a 
reduction in the number of people who 
will need treatment. The reduction of 
adult HIV/AIDS prevalence in Uganda 
from 18.5% to 6% over the last several 
years has reduced the number of those 
eventually needing treatment by nearly 
68% [3]. Unless the incidence of HIV 
is sharply reduced, HIV treatment 
will not be able to keep pace with 
all those who will need therapy [4]. 
Salomon and colleagues’ reafﬁ  rmation 
that only effective prevention will 
make treatment affordable is critically 
important.
Successful treatment and care can 
make prevention more acceptable 
and effective. Widespread access 
to treatment could bring millions 
of people into health-care settings, 
providing new opportunities for 
health-care workers to deliver and 
reinforce HIV prevention messages and 
interventions [4]. Improved access to 
HIV testing provides an entry point to 
both prevention and treatment services 
and provides a unique opportunity 
to identify and target the infected, 
vulnerable, and uninfected with more 
appropriate interventions. All health-
care settings, including HIV treatment 
DOI: 10.1371/journal.pmed.0020039.g001
Figure 1. Projected New Adult Infections and Total Adult Deaths, in Millions, to 2020
This graph represents projections through 2020, and, when there was a choice, 
highlights the more successful iteration of a model. The treatment-centered response, 
therefore, shows data from the optimal-effects model, and the combined response data 
reﬂ  ect the optimistic model.
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sites, should deliver HIV prevention 
services [4].
Prevention can make treatment more 
accessible. The early establishment of 
community-based prevention services 
in rural Ghana was instrumental 
in reducing the stigma of AIDS 
and improving the knowledge and 
attitude of the community prior to the 
development of ART and VCT services 
(K. Torpey, personal communication). 
This process also made it easier for 
community and implementing agencies 
to identify and refer patients needing 
treatment services.
Expanded care and prevention 
activities have synergistic effects. 
Continued effective treatment, care, 
and prevention programs will reduce 
the number of orphans and vulnerable 
children, reduce mother to child 
transmission of the virus, and improve 
the lives of families and the strength of 
communities. 
Integration ensures that prevention 
activities are not neglected. The world 
has a unique opportunity, as ART 
services are launched and expanded, to 
simultaneously bolster prevention efforts 
[4]. Experience in the United States 
indicates that availability of treatment 
can lead to increased risk behavior 
[5]. In addition, the improvement in 
the health, well-being, and longevity of 
people living with AIDS could increase 
the opportunities for HIV transmission. 
Integration can help reduce these 
potential negative impacts of treatment.
Integration can provide opportunities 
to address vulnerable groups more 
effectively. A commitment to providing 
large-scale treatment helps to focus 
attention on communities at greatest 
risk, particularly in lower prevalence 
contexts. This provides an opportunity 
to address the prevention and 
treatment needs of vulnerable groups 
more effectively. 
Treatment resources can help 
improve infrastructure for prevention 
and other health services. The training 
of health providers and improvements 
in laboratory services, pharmacy, 
logistics, commodity management, 
and health information systems can 
beneﬁ  t both treatment and prevention 
services. Further, in many countries, a 
large number of health-care workers 
are themselves infected. Treatment 
can help to preserve the lives and 
productivity of these critically needed 
AIDS prevention and treatment 
workers, as well as those of other health 
professionals. 
A long-term decline in AIDS deaths 
may be preventing new infections. The 
short-term decline in AIDS deaths is 
driven by effective care and treatment 
programs, but a long-term decline 
may be driven by the prevention 
of new infections. Integrated and 
comprehensive strategies are more 
likely to lead to affordable, sustainable 
programs. 
Success requires dramatic expansion 
of both ART and prevention. Globally, 
fewer than one in ﬁ  ve people at high 
risk of infection have access to proven 
HIV prevention interventions [6] and 
less than 10% have access to ART [1]. 
Unless there is a substantial increase 
in commitment and resources for 
both prevention and ART, efforts to 
control HIV/AIDS and mitigate its 
impact will only meet with partial and 
limited success. In addition, to increase 
resources, intensiﬁ  ed commitment is 
required to ensure every opportunity 
is taken to integrate prevention and 
treatment. Future analysis and debate 
should move from comparisons of 
prevention and treatment priorities 
to a sustained analysis of how we can 
reciprocally integrate and strengthen 
prevention and care and use every 
opportunity provided by one to 
reinforce the other. We must focus 
on the development of training, 
monitoring, and quality assurance 
systems that ensure that prevention and 
care are integrated whenever possible. 
The results of Salomon and 
colleagues’ model need to be validated. 
Further operational research is needed 
to validate the ﬁ  ndings of this study.  
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Figure 2. Components of an Integrated Comprehensive HIV/AIDS Program
PMTCT, prevention of mother-to-child transmission; STD, sexually transmitted disease.
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